A Phase 3 interventional study of Esmolol Injection [Brevibloc] in Cirrhosis, Diabetes Mellitus and Oncologic Disorders, sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER). Recruiting at 6 sites in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 254 studies in Diabetes Mellitus with a site in Spain — 20 open to participants now, 29 under way, 5 of them phase 3. Diabetes Mellitus · Spain.
Among the 254 studies in Diabetes Mellitus with a site in Spain, this one is the 49th largest by planned enrollment of the 211 interventional ones that give a count, is one of 8 that started in 2023, is one of 94 in phase 3, reaches primary completion later than 17 of the 28 other live ones, and was the 221st registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →20 of the 254 studies in Diabetes Mellitus with a site in Spain are open now. Recruiting first, the newest first:
Eduardo Luis Martín Javier · Sites in Spain
Ages 18+
Pfizer · Sites in Spain, United States, Brazil and 8 more countries
Ages 18+
Universidad Complutense de Madrid · Sites in Spain
Ages 18–65
Consorci Sanitari de l'Alt Penedès i Garraf · Sites in Spain
Ages 18+
Instituto de Ciencia y Tecnología de Alimentos y Nutrición · Sites in Spain
Ages 20–70
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
254 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 24 · Phase 3 97 · Phase 4 27
First in 1994; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 394 across the 211 interventional studies, 512 across the 42 observational. Of the 193 that completed or were terminated, 89 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
145 of 254 have an industry lead sponsor. The 10 most frequent:
Consorcio Centro de Investigación Biomédica en Red (CIBER) is the lead sponsor of 18 studies on the registry; 6 are open to participants now.
Consorcio Centro de Investigación Biomédica en Red (CIBER) has 2 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
6 of the studies in Diabetes Mellitus with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05769868Phase 3Consorcio Centro de Investigación Biomédica en Red (CIBER)Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments | 2027-03 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT05243368Maimónides Biomedical Research Institute of CórdobaEvaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics | 2026-12-30 |
| NCT07463456Eduardo Luis Martín JavierInter-Device Concordance of Plantar Thermal Asymmetry Measurement (HIK-DM-2026) | 2027-04 |
| NCT07285330Consorci Sanitari de l'Alt Penedès i GarrafDietitian-Nutritionist vs. Day Hospital in the Metabolic Control of Patients With Type 2 Diabetes | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 254 studies in Diabetes Mellitus with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and antineoplastic treatments.
After being informed about the study and potential risks, all patients giving written informed consent will undergo a 10 days screening period to determine eligibility for study entry. At Baseline, patients who meet the eligibility requirements will be allocate in one of the 4 cohorts according to their medical conditions.
Trial design consists in a Screening period, Baseline, and 6 additional visits until Month-36.
All patients will undergo to a conventional echocardiography and echocardiography with esmolol administration at Baseline. This procedure will be performed at the following visits according their cohort.
Other complementary procedures will be the collection of blood samples to determine biomarkers, as well as hematology and biochemistry, vital signs and another explorations.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Consorcio Centro de Investigación Biomédica en Red (CIBER) is the lead sponsor of 18 studies on the registry; 6 are open to participants now.
Compared within Diabetes Mellitus, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 conventional echocardiography without esmolol administration followed by 1 echocardiography with esmolol administration at Baseline and other study visits.
Drug: Esmolol Injection [Brevibloc]
Brevibloc® will be administered intravenously by infusion pump following the administration schedule: Loading dose of 500 μg/kg for 1 minute, followed by a maintenance infusion of 50 μg/kg/minute over 5 minutes. If the target response is not obtained, the loading dose is repeated and the 50 dose is increased by 50 μg/kg/minute to a maximum of 200 μg/kg/minute. The objective response to esmolol beta-blockade is defined as a 15-20% reduction in heart rate, with lower limits of 55 bpm and a systolic blood pressure not less than 90 mmHg and diastolic blood pressure not less than 50 mmHg. The perfusion is kept active while the echocardiography image acquisition is completed (approx. 15-30 min).
Also known as: Anatomical Therapeutic Chemical (ATC) code: C07AB09, Esmolol Hydrochloride
Left Ventricle (LV) ejection fraction
Estimated with 3D echocardiography (Both: convectional and with esmolol administration)
Time frame: At Baseline (Day 1) until Month-24 according to cohort
Peak measurement of global LV systolic longitudinal strain
Estimated with 3D echocardiography (Both: convectional and with esmolol administration)
Time frame: At Baseline (Day 1) until Month-24 according to cohort
Ejection Intraventricular Pressure Difference (EIVPD) measure
Estimated with M-mode echocardiography (Both: convectional and with esmolol administration)
Time frame: At Baseline (Day 1) until Month-24 according to cohort
Ejection fraction
Obtained with 2D echocardiography (Simpson's biplane method)
Time frame: At Baseline (Day 1) until Month-24 according to cohort
Interleukin (IL)-1β
Biochemical variables in blood in relation to the alteration of the different components of the myocardium
Time frame: At Baseline (Day 1) until Month-24 according to cohort
High-sensitivity IL-6 (hsIL-6)
Biochemical variables in blood in relation to the alteration of the different components of the myocardium
Time frame: At Baseline (Day 1) until Month-24 according to cohort
Soluble Suppression of Tumorigenicity 2 (ST-2)
Biochemical variables in blood in relation to the alteration of the different components of the myocardium
Time frame: At Baseline (Day 1) until Month-24 according to cohort
N-terminal fragment of brain natriuretic peptide (NT-proBNP)
Biochemical variables in blood in relation to the alteration of the different components of the myocardium
Time frame: At Baseline (Day 1) until Month-24 according to cohort
Ultrasensitive troponin I (hsTnI)
Biochemical variables in blood in relation to the alteration of the different components of the myocardium
Time frame: At Baseline (Day 1) until Month-24 according to cohort
Procollagen type I terminal propeptide (PICP)
Biochemical variables in blood in relation to the alteration of the different components of the myocardium
Time frame: At Baseline (Day 1) until Month-24 according to cohort
C-terminal telopeptide collagen type I (CITP)
Biochemical variables in blood in relation to the alteration of the different components of the myocardium
Time frame: At Baseline (Day 1) until Month-24 according to cohort
Matrix metalloproteinase-1 (MMP-1)
Biochemical variables in blood in relation to the alteration of the different components of the myocardium
Time frame: At Baseline (Day 1) until Month-24 according to cohort
Started Apr 2023 (actual). Primary completion is estimated for Mar 2027, 47 months after the start.
Of 63 non-industry phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 79. This study's planned 47 months is above that.
Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esmolol
Consorcio Centro de Investigación Biomédica en Red (CIBER)